Protocol Ledger

NCT05836571 · Phase II · ACTIVE NOT RECRUITING

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Interventional Phase II clinical trial protocol NCT05836571 sponsored by National Cancer Institute LAO in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-25 Enrollment: 66 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05836571
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05836571
Protocol FieldVerified Registry Value
NCT IdentifierNCT05836571
Consolidated Lead SponsorNational Cancer Institute LAO
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment66 participants (ESTIMATED)
Registered Start Date2023-10-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI